Rating Overview and Context
On 10 August 2026, MarketsMOJO revised the rating for Sanofi Consumer Healthcare India Ltd from 'Hold' to 'Sell', reflecting a decrease in the Mojo Score from 54 to 43. This adjustment signals a cautious stance on the stock based on a comprehensive evaluation of its current fundamentals, valuation, financial trends, and technical indicators. It is important to note that while the rating change date is fixed, all financial data and returns referenced here are as of 13 September 2026, ensuring investors receive the most up-to-date information.
Here’s How the Stock Looks Today
As of 13 September 2026, Sanofi Consumer Healthcare India Ltd is classified as a smallcap company operating within the Pharmaceuticals & Biotechnology sector. The stock has experienced a downward trend in recent months, with a day change of -1.59%, a one-week decline of -4.16%, and a one-month drop of -11.27%. Over the past six months, the stock has fallen by 8.90%, and year-to-date returns stand at -10.66%. The one-year return is notably negative at -21.51%, indicating sustained underperformance relative to broader market indices.
Quality Assessment
The company’s quality grade is rated as 'good', reflecting solid operational fundamentals and a stable business model within its sector. Over the last five years, Sanofi Consumer Healthcare India Ltd has achieved a net sales compound annual growth rate (CAGR) of 10.10%, while operating profit has grown at a more modest 5.70% annually. Although these figures demonstrate consistent growth, the pace is relatively subdued, suggesting limited expansion potential compared to more dynamic peers in the pharmaceuticals space.
Valuation Considerations
Valuation remains a critical factor in the current rating. The stock is deemed 'very expensive' with a price-to-book (P/B) ratio of 24.3, which is significantly higher than typical benchmarks. This elevated valuation is juxtaposed against a return on equity (ROE) of 69.3%, indicating that while the company is generating strong returns on shareholder equity, the market price may already reflect these expectations, leaving limited margin for further upside. Additionally, the PEG ratio stands at 2.1, suggesting that the stock’s price growth is outpacing earnings growth, which may deter value-conscious investors.
Financial Trend Analysis
Financially, the company holds a 'positive' grade, signalling stable profitability and cash flow generation. However, the latest data shows that profits have remained flat over the past year, with no significant growth recorded. This stagnation, combined with the stock’s negative returns, highlights a disconnect between market valuation and underlying earnings momentum. The stock has also underperformed the BSE500 index over the last three years, one year, and three months, underscoring challenges in maintaining competitive performance within the broader market.
Technical Outlook
From a technical perspective, the stock is graded as 'bearish'. The recent price action, including consistent declines over multiple time frames, suggests downward momentum. This technical weakness may reflect investor concerns about valuation and growth prospects, contributing to the cautious rating. Investors relying on technical analysis may interpret this as a signal to avoid initiating new positions or to consider reducing exposure.
Implications for Investors
The 'Sell' rating from MarketsMOJO indicates that, based on current data as of 13 September 2026, Sanofi Consumer Healthcare India Ltd may not be an attractive investment opportunity at present. The combination of very expensive valuation, flat profit growth, and bearish technical signals suggests limited upside potential and elevated risk. Investors should carefully weigh these factors against their portfolio objectives and risk tolerance before considering exposure to this stock.
Sector and Market Context
Within the Pharmaceuticals & Biotechnology sector, Sanofi Consumer Healthcare India Ltd’s performance contrasts with some peers that have demonstrated stronger growth and more favourable valuations. The stock’s smallcap status also implies higher volatility and liquidity considerations compared to larger, more established companies. Given the sector’s competitive landscape and rapid innovation cycles, maintaining robust growth and valuation metrics is essential for sustained investor confidence.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Summary
In summary, Sanofi Consumer Healthcare India Ltd’s current 'Sell' rating reflects a comprehensive evaluation of its present-day fundamentals and market conditions. While the company maintains good quality and positive financials, its very expensive valuation, lack of profit growth, and bearish technical outlook weigh heavily against it. Investors should consider these factors carefully and monitor any changes in the company’s financial trajectory or market environment that could influence future ratings.
Looking Ahead
For investors tracking Sanofi Consumer Healthcare India Ltd, it is crucial to stay informed about quarterly earnings, sector developments, and broader market trends that may impact the stock’s outlook. Given the current rating and performance metrics, a cautious approach is advisable until clearer signs of valuation rationalisation or earnings acceleration emerge.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
